Berberine - Xintria Pharmaceutical Corporation
Latest Information Update: 21 Jul 2022
At a glance
- Originator Chinese Academy of Medical Sciences
- Developer Xintria Pharmaceutical Corporation
- Class Alkaloids; Antidiarrhoeals; Antiprotozoals; Benzylisoquinolines; Berberine alkaloids; Cardiovascular therapies; Herbal medicines; Heterocyclic compounds with 4 or more rings; Small molecules; Traditional Chinese medicine
- Mechanism of Action Alpha adrenergic receptor antagonists; Cholesterol modulators; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 21 Jul 2022 Discontinued - Phase-II for Cardiovascular disorders in USA (PO)
- 21 Jul 2022 No development reported - Phase-II for Cardiovascular disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA